Bicara Therapeutics (BCAX) Treasury Shares (2023 - 2024)
Bicara Therapeutics' (BCAX) quarterly Treasury Shares came in at $119.6 million in Q2 2024, little changed quarter-over-quarter from $119.6 million in Q1 2024.
Bicara Therapeutics (BCAX) Treasury Shares (2023 - 2024) Analysis & Trends
Bicara Therapeutics' Treasury Shares history runs 2 years deep, the most recent figure standing at $119.6 million for Q2 2024.
- On a quarterly basis, Treasury Shares changed N/A year-over-year to $119.6 million in Q2 2024; TTM through Jun 2024 was $119.6 million, a N/A change from a year earlier, with the FY2023 full-year figure at $119.6 million, changed N/A from the prior year.
- Treasury Shares was little changed at $119.6 million in Q2 2024 per BCAX's latest filing, from $119.6 million in the prior quarter.
- Across five years, Treasury Shares topped out at $119.6 million in Q4 2023 and bottomed at $81.8 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -21,709.08 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 265,401.92 |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 34.70 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 5.14 Mn |
| 10 | Bicara Therapeutics | 1.64 Bn | 1.64 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 119.60 Mn |
| Jun 30, 2024 | 119.60 Mn |
| Mar 31, 2024 | 119.60 Mn |
| Mar 31, 2024 | 119.60 Mn |
| Dec 31, 2023 | 119.60 Mn |
| Dec 31, 2023 | 119.60 Mn |
| Sep 30, 2023 | 81.79 Mn |
| Sep 30, 2023 | 81.79 Mn |